Thyrocare Technologies Ltd AI Stock Analysis
Want to see IN:THYROCARE full AI Analyst Report?
Thyrocare Technologies Ltd (THYROCARE) AI Stock Analysis
Thyrocare Technologies Ltd
(NSE:THYROCARE)
Thyrocare scores moderately. Its greatest strength is financial health: a near debt-free balance sheet, ~78% equity-to-asset ratio, a projected ~27.8% ROE and robust free cash flow of ₹1.95B backed by cash conversion above 1.0x net income. Offsetting this, the stock is in a well-defined downtrend — trading below all key moving averages with negative MACD and subdued RSI — and valuation is rich at a 50.4x P/E given only ~8.7% revenue growth and margins still materially below FY2022 peaks. A ~2.04% dividend yield and improving profitability trend provide partial support, but weak price momentum and premium pricing cap the score. Earnings call and corporate event components were excluded due to insufficient data, with their weight redistributed across the remaining factors.
Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 77.24B
- Dividend Yield
- 1.85%
- Average Volume (3M)
- 65.73K
- Price to Earnings (P/E)
- 55.6
- Beta (1Y)
- 0.67
- Revenue Growth
- 21.99%
- EPS Growth
- 12.77%
- Country
- India
- Employees
- 2,092
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Thyrocare Technologies Ltd Business Overview & Revenue Model
Company Description
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across th...
How the Company Makes Money
Thyrocare primarily makes money by providing diagnostic testing services and earning fees per test or test package processed through its laboratory network. Revenue is generated from (1) individual diagnostic tests and (2) bundled health-check and we...
Thyrocare Technologies Ltd Financial Statement Overview
Summary
A strong balance sheet (score 78) and high-quality cash generation (score 74) anchor the fundamentals: debt-to-equity remains minimal at ~0.087, equity-to-assets is ~78%, ROE is projected to rebound to ~27.8%, and FY2026 free cash flow of ₹1.95B represents ~75% growth with operating cash flow consistently exceeding net income. The income statement (score 62) is the weaker link — revenue growth of ~8.7% in FY2026 follows a flat FY2025 and a ~10.6% decline in FY2023, while net margin (~19.7%) and EBITDA margin (~31.6%) remain well below FY2022 COVID-era peaks, with notable gross margin volatility. Overall, a capital-efficient, low-leverage business on a recovery path but not yet back to peak profitability.
Income Statement
62PositiveBalance Sheet
78PositiveCash Flow
74Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.30B | 8.29B | 6.87B | 5.72B | 5.27B | 5.89B |
| Gross Profit | 5.35B | 3.10B | 4.96B | 1.81B | 3.63B | 4.19B |
| EBITDA | 2.63B | 2.65B | 2.04B | 1.48B | 1.31B | 2.64B |
| Net Income | 1.44B | 1.63B | 915.10M | 707.60M | 644.90M | 1.76B |
Balance Sheet | ||||||
| Total Assets | 7.25B | 7.47B | 6.93B | 6.44B | 6.33B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 2.06B | 2.31B | 1.92B | 1.77B | 1.51B | 1.39B |
| Total Debt | 568.80M | 506.90M | 246.80M | 423.40M | 233.10M | 207.00M |
| Total Liabilities | 1.73B | 1.61B | 1.46B | 1.16B | 975.00M | 810.90M |
| Stockholders Equity | 5.53B | 5.86B | 5.47B | 5.27B | 5.34B | 5.27B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.95B | 1.46B | 1.06B | 856.60M | 755.80M |
| Operating Cash Flow | 0 | 2.16B | 1.91B | 1.68B | 1.29B | 1.13B |
| Investing Cash Flow | 0 | -260.80M | -525.20M | -912.80M | -389.90M | -235.70M |
| Financing Cash Flow | 0 | -1.70B | -1.30B | -848.00M | -861.80M | -894.10M |
Thyrocare Technologies Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Positive. The current price of 504.95 is above the 20-day moving average (MA) of 486.96, below the 50-day MA of 517.72, and above the 200-day MA of 485.92, indicating a neutral trend. The MACD of -2.97 indicates Negative momentum. The RSI at 51.54 is Neutral, neither overbought nor oversold. The STOCH value of 80.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THYROCARE.
Thyrocare Technologies Ltd Peers Comparison
Overall Rating
IN:LALPATHLAB82Outperform
IN:METROPOLIS71Outperform
IN:KRSNAA70Outperform
IN:VIMTALABS69Neutral
IN:VIJAYA67Neutral
IN:THYROCARE58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | INR 329.76B | 56.34 | ― | 0.89% | 16.71% | 9.15% | |
| 71Outperform | INR 117.63B | 52.15 | ― | 0.35% | 19.84% | 41.41% | |
| 70Outperform | INR 16.56B | 16.91 | ― | 0.39% | 15.90% | 15.67% | |
| 69Neutral | INR 20.84B | 25.92 | ― | 0.43% | 11.77% | 1.69% | |
| 67Neutral | INR 158.21B | 77.49 | ― | 0.13% | 24.47% | 34.25% | |
| 58Neutral | INR 80.13B | 55.65 | ― | 1.85% | 21.99% | 12.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:THYROCARE | Thyrocare Technologies Ltd | 504.95 | 2.20 | 0.44% | |
| IN:KRSNAA | Krsnaa Diagnostics Limited | 514.40 | -297.15 | -36.62% | |
| IN:LALPATHLAB | Dr. Lal PathLabs Limited | 1962.15 | 406.93 | 26.17% | |
| IN:METROPOLIS | Metropolis Healthcare Ltd. | 558.60 | 72.21 | 14.84% | |
| IN:VIJAYA | Vijaya Diagnostic Centre Ltd. | 1511.95 | 505.75 | 50.26% | |
| IN:VIMTALABS | Vimta Labs Limited | 471.10 | -137.61 | -22.61% |
Thyrocare Technologies Ltd Corporate Events
Thyrocare Plans October 29 Call on Q2 FY2026-27 Results
Thyrocare Technologies Ltd has scheduled an earnings conference call for analysts and investors to discuss its unaudited financial results for the quarter and half year ended September 30, 2026. The call will be held on Thursday, October 29, 2026, at...
Thyrocare publishes postal ballot notice and opens e‑voting for shareholders
Thyrocare Technologies Ltd has notified the stock exchanges that it has published its postal ballot notice in English and Marathi newspapers, confirming that the ballot documents have been dispatched and providing details of the e‑voting period. The...
Thyrocare exits radiology arm with Rs 141 crore sale to Trovera
Thyrocare Technologies Ltd has approved the sale of its entire shareholding in Nueclear Healthcare Ltd, its material wholly owned subsidiary operating the radiology and diagnostic imaging business, to Trovera Healthcare Pvt Ltd for a total considerat...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
